| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphoid | 64 | 1991 | 108 | 2.360 |
Why?
|
| Methotrexate | 57 | 2006 | 341 | 1.730 |
Why?
|
| Antineoplastic Agents | 50 | 2005 | 1661 | 1.650 |
Why?
|
| Mercaptopurine | 24 | 1998 | 71 | 1.330 |
Why?
|
| Neoplasms | 30 | 2023 | 2758 | 1.210 |
Why?
|
| Meningeal Neoplasms | 23 | 2005 | 183 | 1.150 |
Why?
|
| Macaca mulatta | 64 | 2005 | 494 | 0.990 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 | 2011 | 804 | 0.890 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2000 | 1227 | 0.660 |
Why?
|
| Injections, Spinal | 36 | 2005 | 117 | 0.610 |
Why?
|
| Cyclophosphamide | 14 | 2005 | 419 | 0.590 |
Why?
|
| Leukemia | 16 | 1996 | 375 | 0.580 |
Why?
|
| Internet | 2 | 2022 | 378 | 0.530 |
Why?
|
| Central Nervous System Diseases | 10 | 1996 | 105 | 0.490 |
Why?
|
| Cancer Survivors | 1 | 2018 | 199 | 0.470 |
Why?
|
| Child | 114 | 2023 | 24237 | 0.460 |
Why?
|
| Survivors | 2 | 2022 | 345 | 0.440 |
Why?
|
| Cytarabine | 15 | 1999 | 98 | 0.430 |
Why?
|
| Child, Preschool | 80 | 2018 | 13887 | 0.370 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2004 | 178 | 0.360 |
Why?
|
| Humans | 202 | 2023 | 123169 | 0.360 |
Why?
|
| Lymphocytes | 12 | 1993 | 401 | 0.350 |
Why?
|
| Tretinoin | 4 | 1995 | 116 | 0.340 |
Why?
|
| Injections, Intravenous | 26 | 1996 | 252 | 0.330 |
Why?
|
| Pyrazoles | 5 | 1998 | 303 | 0.320 |
Why?
|
| Ribonucleosides | 6 | 1985 | 15 | 0.310 |
Why?
|
| Asparaginase | 8 | 1998 | 41 | 0.300 |
Why?
|
| Cytidine | 3 | 1993 | 9 | 0.300 |
Why?
|
| Medical Oncology | 2 | 2011 | 214 | 0.300 |
Why?
|
| Zidovudine | 5 | 1993 | 22 | 0.300 |
Why?
|
| Drug Evaluation | 19 | 1992 | 111 | 0.290 |
Why?
|
| Male | 130 | 2018 | 60082 | 0.290 |
Why?
|
| Half-Life | 21 | 1995 | 156 | 0.290 |
Why?
|
| Kinetics | 28 | 1992 | 1313 | 0.290 |
Why?
|
| Adolescent | 84 | 2018 | 19103 | 0.280 |
Why?
|
| Injections, Intraventricular | 19 | 2000 | 65 | 0.280 |
Why?
|
| Drug Administration Schedule | 23 | 1999 | 730 | 0.280 |
Why?
|
| Azacitidine | 4 | 1993 | 54 | 0.280 |
Why?
|
| Animals | 82 | 2005 | 33749 | 0.280 |
Why?
|
| Infusions, Intravenous | 18 | 2000 | 537 | 0.280 |
Why?
|
| Camptothecin | 4 | 1996 | 76 | 0.270 |
Why?
|
| Meningitis | 4 | 2005 | 99 | 0.260 |
Why?
|
| Metabolic Clearance Rate | 16 | 2000 | 142 | 0.260 |
Why?
|
| Pediatrics | 3 | 2018 | 1139 | 0.260 |
Why?
|
| gamma-Glutamyl Hydrolase | 3 | 2004 | 10 | 0.260 |
Why?
|
| Anthraquinones | 3 | 1993 | 9 | 0.250 |
Why?
|
| Coformycin | 5 | 1982 | 7 | 0.250 |
Why?
|
| Africa South of the Sahara | 2 | 2023 | 121 | 0.250 |
Why?
|
| Fluorouracil | 4 | 1992 | 128 | 0.250 |
Why?
|
| Hematology | 2 | 2018 | 38 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 1995 | 232 | 0.230 |
Why?
|
| Nucleotidases | 6 | 1982 | 6 | 0.220 |
Why?
|
| Purine-Nucleoside Phosphorylase | 5 | 1982 | 9 | 0.210 |
Why?
|
| Brain Neoplasms | 7 | 1998 | 1235 | 0.200 |
Why?
|
| Adult | 72 | 2006 | 29062 | 0.200 |
Why?
|
| Topotecan | 7 | 2003 | 49 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 12 | 1999 | 338 | 0.200 |
Why?
|
| B-Lymphocytes | 11 | 1995 | 518 | 0.190 |
Why?
|
| Pentosyltransferases | 4 | 1982 | 18 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2000 | 1683 | 0.190 |
Why?
|
| Subarachnoid Space | 3 | 2000 | 24 | 0.190 |
Why?
|
| Biological Availability | 13 | 1998 | 128 | 0.180 |
Why?
|
| Adenosine Deaminase | 6 | 1982 | 74 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 169 | 0.180 |
Why?
|
| T-Lymphocytes | 16 | 1987 | 1677 | 0.170 |
Why?
|
| Asparagine | 3 | 1993 | 22 | 0.170 |
Why?
|
| Thiotepa | 5 | 1996 | 15 | 0.170 |
Why?
|
| Thioguanine | 6 | 1997 | 21 | 0.170 |
Why?
|
| Lymphoma | 6 | 1989 | 321 | 0.170 |
Why?
|
| Aziridines | 4 | 1998 | 11 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1992 | 532 | 0.170 |
Why?
|
| Benzoquinones | 4 | 1998 | 19 | 0.170 |
Why?
|
| Infant | 41 | 2018 | 12348 | 0.170 |
Why?
|
| Nucleoside Deaminases | 4 | 1982 | 26 | 0.160 |
Why?
|
| Melphalan | 2 | 1995 | 49 | 0.160 |
Why?
|
| Administration, Oral | 13 | 1998 | 670 | 0.150 |
Why?
|
| Triazoles | 2 | 1990 | 138 | 0.150 |
Why?
|
| Pyrimidines | 2 | 1992 | 373 | 0.150 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 32 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 78 | 0.150 |
Why?
|
| Clinical Trials as Topic | 9 | 2011 | 1088 | 0.140 |
Why?
|
| Time Factors | 24 | 1995 | 6217 | 0.140 |
Why?
|
| Female | 74 | 2018 | 65500 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1996 | 96 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2018 | 123 | 0.140 |
Why?
|
| Combined Modality Therapy | 10 | 1998 | 1239 | 0.140 |
Why?
|
| Acridines | 2 | 1998 | 8 | 0.140 |
Why?
|
| Cell Survival | 10 | 1994 | 806 | 0.130 |
Why?
|
| Central Nervous System | 3 | 1995 | 254 | 0.130 |
Why?
|
| Genes, p53 | 2 | 1994 | 213 | 0.130 |
Why?
|
| Infusions, Parenteral | 9 | 2000 | 100 | 0.130 |
Why?
|
| Polyglutamic Acid | 2 | 1987 | 4 | 0.130 |
Why?
|
| Amifostine | 1 | 1995 | 14 | 0.130 |
Why?
|
| Nutritional Status | 1 | 1998 | 304 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 7 | 1994 | 1061 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 286 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 375 | 0.120 |
Why?
|
| Leukemia, Experimental | 3 | 1988 | 15 | 0.120 |
Why?
|
| Burkitt Lymphoma | 9 | 1999 | 145 | 0.120 |
Why?
|
| Prednisone | 8 | 1998 | 274 | 0.120 |
Why?
|
| Sarcoma, Ewing | 5 | 1998 | 113 | 0.120 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 3 | 1995 | 9 | 0.110 |
Why?
|
| Meningioma | 1 | 1995 | 120 | 0.110 |
Why?
|
| Hypoxanthines | 3 | 1993 | 4 | 0.110 |
Why?
|
| Vincristine | 11 | 1998 | 195 | 0.110 |
Why?
|
| Rhabdomyosarcoma | 6 | 1998 | 200 | 0.110 |
Why?
|
| Prognosis | 8 | 2011 | 4507 | 0.110 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1990 | 6 | 0.110 |
Why?
|
| Genes, Immunoglobulin | 2 | 1995 | 33 | 0.110 |
Why?
|
| Azirines | 2 | 1984 | 2 | 0.100 |
Why?
|
| Myelin Basic Protein | 2 | 1985 | 69 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 1991 | 29 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1991 | 57 | 0.100 |
Why?
|
| Uracil | 1 | 1992 | 14 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 607 | 0.100 |
Why?
|
| Liver | 6 | 1998 | 1734 | 0.100 |
Why?
|
| Peptides | 2 | 1987 | 794 | 0.100 |
Why?
|
| Testicular Neoplasms | 4 | 1985 | 132 | 0.100 |
Why?
|
| Brain | 10 | 2000 | 2961 | 0.100 |
Why?
|
| Circadian Rhythm | 4 | 1991 | 269 | 0.100 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1991 | 5 | 0.100 |
Why?
|
| Nervous System Neoplasms | 3 | 1989 | 11 | 0.100 |
Why?
|
| Brain Diseases | 5 | 1990 | 296 | 0.100 |
Why?
|
| Macaca | 3 | 1983 | 62 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 10 | 1990 | 2056 | 0.100 |
Why?
|
| Retroviridae Infections | 1 | 1991 | 10 | 0.100 |
Why?
|
| Cerebral Ventricles | 6 | 2000 | 81 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 217 | 0.100 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 2 | 1993 | 35 | 0.090 |
Why?
|
| Up-Regulation | 2 | 1995 | 863 | 0.090 |
Why?
|
| Recurrence | 12 | 1999 | 1422 | 0.090 |
Why?
|
| Protein Binding | 6 | 1998 | 1741 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1262 | 0.090 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 507 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 247 | 0.090 |
Why?
|
| Attention | 2 | 1990 | 197 | 0.090 |
Why?
|
| Infusion Pumps | 1 | 1990 | 33 | 0.090 |
Why?
|
| Drug Interactions | 6 | 1992 | 254 | 0.090 |
Why?
|
| Physicians, Women | 1 | 2011 | 46 | 0.090 |
Why?
|
| BCG Vaccine | 4 | 1979 | 115 | 0.090 |
Why?
|
| Genetic Therapy | 3 | 2000 | 678 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 3 | 1985 | 577 | 0.090 |
Why?
|
| Rosette Formation | 4 | 1982 | 17 | 0.090 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 1386 | 0.080 |
Why?
|
| Antigens, Surface | 4 | 1988 | 121 | 0.080 |
Why?
|
| Antiviral Agents | 3 | 1995 | 747 | 0.080 |
Why?
|
| Folic Acid Antagonists | 2 | 1988 | 17 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 1995 | 477 | 0.080 |
Why?
|
| Drug Resistance | 7 | 1993 | 256 | 0.080 |
Why?
|
| Phosphoribosyl Pyrophosphate | 2 | 1986 | 2 | 0.080 |
Why?
|
| Catheterization | 2 | 1990 | 235 | 0.080 |
Why?
|
| Quinazolines | 3 | 1988 | 175 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2010 | 114 | 0.080 |
Why?
|
| Doxorubicin | 5 | 1996 | 299 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1999 | 126 | 0.080 |
Why?
|
| Injections, Intramuscular | 5 | 1993 | 192 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 252 | 0.080 |
Why?
|
| Growth Hormone | 4 | 1984 | 150 | 0.080 |
Why?
|
| DNA | 2 | 1993 | 1592 | 0.080 |
Why?
|
| Leucovorin | 4 | 1995 | 50 | 0.080 |
Why?
|
| Deoxyribonucleosides | 1 | 1988 | 2 | 0.080 |
Why?
|
| Pyrimidine Nucleosides | 1 | 1988 | 2 | 0.080 |
Why?
|
| Acute Disease | 10 | 1986 | 1094 | 0.080 |
Why?
|
| Razoxane | 2 | 1996 | 10 | 0.080 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1988 | 2 | 0.080 |
Why?
|
| Hydantoins | 1 | 1988 | 5 | 0.080 |
Why?
|
| Ifosfamide | 1 | 1988 | 36 | 0.080 |
Why?
|
| Phenytoin | 1 | 1988 | 64 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 230 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 1988 | 42 | 0.070 |
Why?
|
| Radiation Injuries | 4 | 1985 | 140 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 1990 | 293 | 0.070 |
Why?
|
| Models, Biological | 6 | 1997 | 1441 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 1993 | 1019 | 0.070 |
Why?
|
| Memory Disorders | 1 | 1990 | 235 | 0.070 |
Why?
|
| Prednisolone | 2 | 1987 | 73 | 0.070 |
Why?
|
| Morphine | 1 | 1987 | 87 | 0.070 |
Why?
|
| Neutropenia | 6 | 1998 | 202 | 0.070 |
Why?
|
| Genes | 6 | 1989 | 444 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2005 | 751 | 0.070 |
Why?
|
| Purines | 3 | 1981 | 107 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2011 | 678 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1987 | 96 | 0.070 |
Why?
|
| Paclitaxel | 3 | 1997 | 121 | 0.070 |
Why?
|
| Allopurinol | 2 | 1986 | 70 | 0.070 |
Why?
|
| Hepatitis B | 2 | 1986 | 159 | 0.070 |
Why?
|
| Testis | 3 | 1987 | 405 | 0.070 |
Why?
|
| Isoenzymes | 4 | 1993 | 223 | 0.070 |
Why?
|
| Pentosephosphates | 1 | 1986 | 8 | 0.070 |
Why?
|
| Leukocyte Count | 9 | 1992 | 247 | 0.070 |
Why?
|
| Amitriptyline | 1 | 1986 | 27 | 0.070 |
Why?
|
| Catheters, Indwelling | 3 | 1990 | 155 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 1996 | 1008 | 0.060 |
Why?
|
| Otitis | 1 | 1985 | 11 | 0.060 |
Why?
|
| Leydig Cells | 1 | 1985 | 20 | 0.060 |
Why?
|
| Medication Errors | 2 | 2004 | 184 | 0.060 |
Why?
|
| Daunorubicin | 3 | 1999 | 27 | 0.060 |
Why?
|
| Pentostatin | 5 | 1982 | 11 | 0.060 |
Why?
|
| Complement System Proteins | 3 | 1982 | 58 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 1982 | 65 | 0.060 |
Why?
|
| Communication Disorders | 1 | 1985 | 8 | 0.060 |
Why?
|
| Dexamethasone | 1 | 1987 | 272 | 0.060 |
Why?
|
| Mastoiditis | 1 | 1985 | 31 | 0.060 |
Why?
|
| Leukemia L5178 | 1 | 1985 | 1 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1982 | 62 | 0.060 |
Why?
|
| Thioinosine | 1 | 1984 | 1 | 0.060 |
Why?
|
| Inosine | 1 | 1984 | 11 | 0.060 |
Why?
|
| Probenecid | 3 | 2000 | 4 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1991 | 1117 | 0.060 |
Why?
|
| Ribavirin | 1 | 1985 | 79 | 0.060 |
Why?
|
| Antibodies | 3 | 1991 | 369 | 0.060 |
Why?
|
| Brain Abscess | 1 | 1985 | 57 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 1984 | 28 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 1994 | 94 | 0.060 |
Why?
|
| Folic Acid | 1 | 1987 | 292 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1985 | 107 | 0.060 |
Why?
|
| Absorption | 2 | 1998 | 52 | 0.060 |
Why?
|
| Aminoacridines | 1 | 1984 | 1 | 0.060 |
Why?
|
| Osteosarcoma | 5 | 1998 | 257 | 0.060 |
Why?
|
| Receptors, Immunologic | 3 | 1990 | 110 | 0.060 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 71 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 194 | 0.060 |
Why?
|
| Cell Line | 10 | 1995 | 2771 | 0.060 |
Why?
|
| Injections, Subcutaneous | 3 | 1989 | 126 | 0.060 |
Why?
|
| Stomatitis | 2 | 1985 | 13 | 0.060 |
Why?
|
| Receptors, Fc | 2 | 1980 | 28 | 0.060 |
Why?
|
| Leukemia L1210 | 2 | 1984 | 4 | 0.060 |
Why?
|
| Leukopenia | 3 | 1991 | 44 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 4 | 1992 | 43 | 0.060 |
Why?
|
| Sarcoma | 3 | 1996 | 194 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 3 | 2000 | 93 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 1994 | 30 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 1988 | 262 | 0.050 |
Why?
|
| Blood-Brain Barrier | 4 | 1991 | 141 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1513 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 36 | 0.050 |
Why?
|
| Tetrahydrouridine | 1 | 1982 | 2 | 0.050 |
Why?
|
| Bone Neoplasms | 5 | 1998 | 427 | 0.050 |
Why?
|
| Seminiferous Tubules | 1 | 1982 | 14 | 0.050 |
Why?
|
| Vidarabine | 1 | 1982 | 79 | 0.050 |
Why?
|
| Agranulocytosis | 4 | 1990 | 14 | 0.050 |
Why?
|
| Intelligence | 2 | 1990 | 98 | 0.050 |
Why?
|
| Dideoxyadenosine | 2 | 1999 | 3 | 0.050 |
Why?
|
| Uridine | 1 | 1982 | 34 | 0.050 |
Why?
|
| Species Specificity | 3 | 1990 | 548 | 0.050 |
Why?
|
| Bacterial Infections | 3 | 1991 | 305 | 0.050 |
Why?
|
| Interleukin-2 | 4 | 1992 | 229 | 0.050 |
Why?
|
| Neuroblastoma | 2 | 1998 | 509 | 0.050 |
Why?
|
| Extracellular Space | 1 | 1982 | 89 | 0.050 |
Why?
|
| Leukemia, Myeloid | 2 | 1981 | 85 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 1981 | 9 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 1994 | 330 | 0.050 |
Why?
|
| Drug Therapy, Combination | 11 | 1982 | 1151 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 10010 | 0.050 |
Why?
|
| Intestinal Absorption | 3 | 1993 | 190 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 1993 | 795 | 0.050 |
Why?
|
| Testosterone | 2 | 1985 | 462 | 0.050 |
Why?
|
| Drug Stability | 2 | 1993 | 55 | 0.050 |
Why?
|
| Binding Sites, Antibody | 2 | 1989 | 98 | 0.050 |
Why?
|
| Hypoxanthine | 2 | 1993 | 6 | 0.050 |
Why?
|
| Sezary Syndrome | 1 | 1980 | 12 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1998 | 130 | 0.050 |
Why?
|
| Adenosine | 1 | 1981 | 126 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 1985 | 555 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2018 | 8108 | 0.050 |
Why?
|
| Peroxidases | 2 | 1984 | 26 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 1984 | 69 | 0.040 |
Why?
|
| Cytidine Deaminase | 3 | 1993 | 31 | 0.040 |
Why?
|
| Neuropsychological Tests | 3 | 1990 | 923 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1980 | 90 | 0.040 |
Why?
|
| Uricosuric Agents | 1 | 2000 | 5 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1980 | 33 | 0.040 |
Why?
|
| Monocytes | 4 | 1981 | 346 | 0.040 |
Why?
|
| Remission, Spontaneous | 9 | 1979 | 68 | 0.040 |
Why?
|
| Pinocytosis | 2 | 1977 | 7 | 0.040 |
Why?
|
| Granulocytes | 3 | 1979 | 65 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1991 | 151 | 0.040 |
Why?
|
| Middle Aged | 14 | 2004 | 25994 | 0.040 |
Why?
|
| Bone Marrow Diseases | 2 | 1993 | 40 | 0.040 |
Why?
|
| Chemotaxis | 2 | 1977 | 55 | 0.040 |
Why?
|
| Cisplatin | 1 | 1981 | 242 | 0.040 |
Why?
|
| Bone Marrow | 4 | 1991 | 323 | 0.040 |
Why?
|
| Cytotoxins | 2 | 1998 | 20 | 0.040 |
Why?
|
| Thrombocytopenia | 5 | 1998 | 228 | 0.040 |
Why?
|
| Follow-Up Studies | 8 | 1990 | 5047 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1997 | 102 | 0.040 |
Why?
|
| Gene Amplification | 2 | 1998 | 228 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 1979 | 41 | 0.040 |
Why?
|
| Idarubicin | 1 | 1999 | 7 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2004 | 162 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 25 | 0.040 |
Why?
|
| Adrenal Insufficiency | 1 | 1979 | 29 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 1980 | 96 | 0.040 |
Why?
|
| Antibody Formation | 3 | 1992 | 256 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1983 | 29 | 0.040 |
Why?
|
| Piperazines | 1 | 1980 | 230 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 108 | 0.040 |
Why?
|
| Thionucleotides | 2 | 1998 | 19 | 0.040 |
Why?
|
| Saliva | 1 | 1979 | 113 | 0.040 |
Why?
|
| Retinal Neoplasms | 1 | 1999 | 98 | 0.040 |
Why?
|
| Immunoglobulins | 5 | 1987 | 169 | 0.040 |
Why?
|
| Risk | 3 | 2006 | 747 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 100 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2000 | 653 | 0.040 |
Why?
|
| Mice | 12 | 1995 | 17494 | 0.040 |
Why?
|
| Drug Overdose | 2 | 2004 | 63 | 0.040 |
Why?
|
| Rats | 5 | 1990 | 3654 | 0.040 |
Why?
|
| Carbon Radioisotopes | 2 | 1993 | 71 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2006 | 12129 | 0.040 |
Why?
|
| Fetus | 1 | 1980 | 573 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 1987 | 382 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 170 | 0.030 |
Why?
|
| Taxoids | 1 | 1997 | 65 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 1989 | 413 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 1978 | 203 | 0.030 |
Why?
|
| Trimetrexate | 4 | 1995 | 4 | 0.030 |
Why?
|
| Mathematics | 2 | 1988 | 100 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 306 | 0.030 |
Why?
|
| Macrophages | 3 | 1979 | 605 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1976 | 202 | 0.030 |
Why?
|
| Calcinosis | 2 | 1990 | 170 | 0.030 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 1995 | 2 | 0.030 |
Why?
|
| Mycobacterium bovis | 1 | 1976 | 35 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 1995 | 8 | 0.030 |
Why?
|
| Meninges | 1 | 1995 | 16 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 271 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1975 | 90 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 1995 | 8 | 0.030 |
Why?
|
| Cell Cycle | 2 | 1993 | 614 | 0.030 |
Why?
|
| Food | 2 | 1986 | 125 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1995 | 24 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 99 | 0.030 |
Why?
|
| Blood Proteins | 2 | 1987 | 116 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 1975 | 60 | 0.030 |
Why?
|
| Phagocytosis | 2 | 1978 | 169 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 1996 | 86 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 614 | 0.030 |
Why?
|
| AIDS Dementia Complex | 2 | 1993 | 12 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1987 | 105 | 0.030 |
Why?
|
| Spinal Puncture | 4 | 1979 | 53 | 0.030 |
Why?
|
| Didanosine | 2 | 1995 | 5 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 1998 | 481 | 0.030 |
Why?
|
| Leukocytes | 2 | 1981 | 207 | 0.030 |
Why?
|
| Patient Isolators | 1 | 1974 | 2 | 0.030 |
Why?
|
| Protective Clothing | 1 | 1974 | 7 | 0.030 |
Why?
|
| Candidiasis | 1 | 1975 | 129 | 0.030 |
Why?
|
| Codon | 1 | 1994 | 96 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 229 | 0.030 |
Why?
|
| Posture | 1 | 1995 | 152 | 0.030 |
Why?
|
| Heart | 2 | 1996 | 723 | 0.030 |
Why?
|
| Quinolinic Acid | 1 | 1993 | 10 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 1993 | 9 | 0.030 |
Why?
|
| Glucuronates | 1 | 1993 | 6 | 0.030 |
Why?
|
| Clone Cells | 2 | 1991 | 163 | 0.030 |
Why?
|
| Inactivation, Metabolic | 1 | 1993 | 32 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 1986 | 73 | 0.030 |
Why?
|
| Zalcitabine | 2 | 1990 | 4 | 0.030 |
Why?
|
| Platelet Count | 2 | 1992 | 133 | 0.030 |
Why?
|
| Uridine Kinase | 1 | 1993 | 2 | 0.030 |
Why?
|
| Radiotherapy Dosage | 3 | 1985 | 185 | 0.030 |
Why?
|
| Drug Compounding | 1 | 1993 | 34 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 1993 | 46 | 0.030 |
Why?
|
| Enzymes, Immobilized | 1 | 1993 | 6 | 0.030 |
Why?
|
| Hydrocortisone | 3 | 1985 | 215 | 0.030 |
Why?
|
| Aminolevulinic Acid | 1 | 1993 | 9 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1993 | 36 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1993 | 155 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1993 | 100 | 0.030 |
Why?
|
| Guanosine Triphosphate | 2 | 1998 | 47 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 1998 | 18 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1993 | 98 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 1974 | 372 | 0.020 |
Why?
|
| 5'-Nucleotidase | 2 | 1982 | 15 | 0.020 |
Why?
|
| Paralysis | 1 | 1992 | 35 | 0.020 |
Why?
|
| Biopsy | 2 | 1993 | 1237 | 0.020 |
Why?
|
| Drug Industry | 1 | 1991 | 46 | 0.020 |
Why?
|
| Glioma | 2 | 1996 | 496 | 0.020 |
Why?
|
| Necrosis | 1 | 1992 | 204 | 0.020 |
Why?
|
| Haplorhini | 4 | 1979 | 123 | 0.020 |
Why?
|
| Mutation | 3 | 1994 | 5773 | 0.020 |
Why?
|
| DNA, Neoplasm | 3 | 1990 | 300 | 0.020 |
Why?
|
| Vidarabine Phosphate | 1 | 1990 | 1 | 0.020 |
Why?
|
| Perfusion | 2 | 1984 | 197 | 0.020 |
Why?
|
| Cross Infection | 1 | 1974 | 331 | 0.020 |
Why?
|
| Cell Membrane | 3 | 1983 | 459 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2004 | 2477 | 0.020 |
Why?
|
| Genotype | 2 | 1994 | 2542 | 0.020 |
Why?
|
| Aged | 4 | 2004 | 19080 | 0.020 |
Why?
|
| Immunoglobulin M | 3 | 1980 | 210 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 1002 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 1213 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1991 | 89 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 2 | 1981 | 11 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1990 | 285 | 0.020 |
Why?
|
| HIV-1 | 1 | 1993 | 465 | 0.020 |
Why?
|
| Karyotyping | 3 | 1998 | 330 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1992 | 305 | 0.020 |
Why?
|
| Luteinizing Hormone | 3 | 1985 | 120 | 0.020 |
Why?
|
| Skin | 1 | 1993 | 505 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 1987 | 76 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 1993 | 1414 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1990 | 239 | 0.020 |
Why?
|
| Career Choice | 1 | 2011 | 143 | 0.020 |
Why?
|
| Biological Transport, Active | 2 | 1987 | 87 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 765 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 332 | 0.020 |
Why?
|
| Verbal Learning | 1 | 1990 | 66 | 0.020 |
Why?
|
| Erythrocytes | 3 | 1998 | 206 | 0.020 |
Why?
|
| Killer Cells, Natural | 3 | 1981 | 319 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 3 | 1985 | 186 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3555 | 0.020 |
Why?
|
| Chromosome Deletion | 2 | 1992 | 638 | 0.020 |
Why?
|
| Alanine Transaminase | 2 | 1987 | 151 | 0.020 |
Why?
|
| Radiotherapy | 3 | 1979 | 135 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 97 | 0.020 |
Why?
|
| Nervous System | 2 | 1988 | 128 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1989 | 21 | 0.020 |
Why?
|
| Leukemia P388 | 1 | 1988 | 2 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 1990 | 94 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1993 | 359 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 123 | 0.020 |
Why?
|
| Specimen Handling | 2 | 1987 | 141 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 1994 | 1907 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1988 | 51 | 0.020 |
Why?
|
| Logistic Models | 1 | 1993 | 1793 | 0.020 |
Why?
|
| Fever | 1 | 1991 | 296 | 0.020 |
Why?
|
| Physostigmine | 1 | 1988 | 9 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 1989 | 153 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1988 | 99 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 349 | 0.020 |
Why?
|
| RNA | 2 | 1989 | 572 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1980 | 770 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 651 | 0.020 |
Why?
|
| Sexual Maturation | 2 | 1985 | 48 | 0.020 |
Why?
|
| Permeability | 1 | 1988 | 118 | 0.020 |
Why?
|
| Fluconazole | 1 | 1988 | 47 | 0.020 |
Why?
|
| Age Factors | 2 | 1989 | 2802 | 0.020 |
Why?
|
| Intracranial Pressure | 3 | 1978 | 181 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 1981 | 20 | 0.020 |
Why?
|
| Blood Platelets | 2 | 1984 | 333 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 1987 | 75 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1993 | 560 | 0.020 |
Why?
|
| Orbital Neoplasms | 2 | 1978 | 65 | 0.020 |
Why?
|
| Base Sequence | 4 | 1995 | 3091 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1988 | 567 | 0.020 |
Why?
|
| Cognition | 2 | 2006 | 735 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1987 | 122 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 1976 | 22 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1986 | 52 | 0.020 |
Why?
|
| United States | 3 | 2011 | 10631 | 0.020 |
Why?
|
| Remission Induction | 2 | 1999 | 300 | 0.020 |
Why?
|
| HIV | 1 | 1987 | 179 | 0.020 |
Why?
|
| Cell Count | 1 | 1986 | 250 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 3868 | 0.020 |
Why?
|
| Blood Cells | 1 | 1986 | 49 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 993 | 0.020 |
Why?
|
| Pentetic Acid | 2 | 1985 | 10 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1988 | 1081 | 0.020 |
Why?
|
| Reference Standards | 1 | 1986 | 240 | 0.020 |
Why?
|
| Cranial Fossa, Posterior | 1 | 1985 | 14 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1988 | 501 | 0.020 |
Why?
|
| Nucleotides | 1 | 1985 | 92 | 0.020 |
Why?
|
| Translocation, Genetic | 2 | 1995 | 352 | 0.020 |
Why?
|
| Cranial Irradiation | 2 | 1998 | 69 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1985 | 86 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1985 | 58 | 0.010 |
Why?
|
| Glutamates | 1 | 1985 | 69 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1985 | 93 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1990 | 553 | 0.010 |
Why?
|
| Body Weight | 1 | 1989 | 1001 | 0.010 |
Why?
|
| Arabinofuranosyluracil | 1 | 1984 | 4 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1985 | 287 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1984 | 10 | 0.010 |
Why?
|
| Amsacrine | 1 | 1984 | 5 | 0.010 |
Why?
|
| Biological Transport | 1 | 1985 | 347 | 0.010 |
Why?
|
| Algorithms | 1 | 1991 | 1592 | 0.010 |
Why?
|
| Neurocognitive Disorders | 1 | 1984 | 67 | 0.010 |
Why?
|
| Glutamine | 1 | 1985 | 195 | 0.010 |
Why?
|
| Lymphocytes, Null | 1 | 1983 | 2 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1985 | 200 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 1582 | 0.010 |
Why?
|
| In Vitro Techniques | 4 | 1979 | 966 | 0.010 |
Why?
|
| Phenotype | 6 | 1990 | 4228 | 0.010 |
Why?
|
| Kidney | 2 | 1987 | 1337 | 0.010 |
Why?
|
| Diffusion | 1 | 1983 | 58 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1980 | 459 | 0.010 |
Why?
|
| Drainage | 1 | 2004 | 256 | 0.010 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 1995 | 9 | 0.010 |
Why?
|
| DNA Replication | 1 | 1985 | 342 | 0.010 |
Why?
|
| Arabinonucleosides | 1 | 1982 | 32 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1982 | 48 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1986 | 434 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 1982 | 14 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1982 | 677 | 0.010 |
Why?
|
| Oxazoles | 1 | 1982 | 27 | 0.010 |
Why?
|
| Immunoglobulin A | 2 | 1980 | 197 | 0.010 |
Why?
|
| Adenosylhomocysteinase | 1 | 1982 | 3 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 1388 | 0.010 |
Why?
|
| Isoxazoles | 1 | 1982 | 31 | 0.010 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1982 | 71 | 0.010 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1981 | 6 | 0.010 |
Why?
|
| Hydrolases | 1 | 1982 | 52 | 0.010 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1983 | 86 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1981 | 21 | 0.010 |
Why?
|
| Thyrotropin | 3 | 1991 | 58 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1981 | 36 | 0.010 |
Why?
|
| Receptors, Complement | 1 | 1981 | 31 | 0.010 |
Why?
|
| Misonidazole | 1 | 1981 | 2 | 0.010 |
Why?
|
| Nausea | 1 | 1981 | 97 | 0.010 |
Why?
|
| Cytochalasin B | 1 | 1980 | 9 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1980 | 7 | 0.010 |
Why?
|
| Colchicine | 1 | 1980 | 43 | 0.010 |
Why?
|
| Vomiting | 1 | 1981 | 115 | 0.010 |
Why?
|
| Epilepsy | 1 | 1988 | 858 | 0.010 |
Why?
|
| Nitroimidazoles | 1 | 1981 | 52 | 0.010 |
Why?
|
| Phosphorus Metabolism Disorders | 1 | 1980 | 1 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 39 | 0.010 |
Why?
|
| Uremia | 1 | 1980 | 35 | 0.010 |
Why?
|
| Demyelinating Diseases | 1 | 1980 | 67 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1976 | 23 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 1980 | 36 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1979 | 2 | 0.010 |
Why?
|
| Cephalothin | 1 | 1979 | 6 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1979 | 33 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1985 | 1877 | 0.010 |
Why?
|
| Seizures | 1 | 1985 | 874 | 0.010 |
Why?
|
| Binding Sites | 2 | 1979 | 1291 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1979 | 26 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 57 | 0.010 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 1979 | 3 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1979 | 43 | 0.010 |
Why?
|
| Anemia, Aplastic | 2 | 1976 | 53 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1981 | 216 | 0.010 |
Why?
|
| Public Policy | 1 | 1999 | 51 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1999 | 47 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1980 | 79 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1979 | 76 | 0.010 |
Why?
|
| Gentamicins | 1 | 1979 | 95 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 132 | 0.010 |
Why?
|
| Hyperkalemia | 1 | 1980 | 65 | 0.010 |
Why?
|
| Lysosomes | 1 | 1980 | 232 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1979 | 50 | 0.010 |
Why?
|
| Maxillary Sinus | 1 | 1978 | 14 | 0.010 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1978 | 16 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1982 | 644 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1977 | 151 | 0.010 |
Why?
|
| DNA Adducts | 1 | 1998 | 78 | 0.010 |
Why?
|
| Neoplasm Seeding | 1 | 1978 | 13 | 0.010 |
Why?
|
| Rabbits | 2 | 1980 | 708 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1999 | 235 | 0.010 |
Why?
|
| Cellulitis | 2 | 1990 | 64 | 0.010 |
Why?
|
| Facial Injuries | 1 | 1978 | 22 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1978 | 31 | 0.010 |
Why?
|
| Hormones | 1 | 1979 | 191 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1998 | 313 | 0.010 |
Why?
|
| RNA, Neoplasm | 2 | 1989 | 138 | 0.010 |
Why?
|
| Neurotoxins | 1 | 1978 | 56 | 0.010 |
Why?
|
| Levamisole | 1 | 1977 | 4 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1981 | 387 | 0.010 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1977 | 18 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1977 | 12 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1991 | 9 | 0.010 |
Why?
|
| Sinusitis | 1 | 1978 | 117 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1978 | 659 | 0.010 |
Why?
|
| Blindness | 1 | 1977 | 72 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1979 | 293 | 0.010 |
Why?
|
| Chickens | 1 | 1976 | 636 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1976 | 30 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1990 | 771 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 757 | 0.010 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1976 | 9 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1976 | 80 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1978 | 201 | 0.010 |
Why?
|
| Cell Movement | 2 | 1977 | 831 | 0.010 |
Why?
|
| Transaminases | 1 | 1996 | 32 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 1975 | 27 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1980 | 507 | 0.010 |
Why?
|
| Brain Stem | 1 | 1996 | 115 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 214 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 57 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1995 | 85 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 1995 | 22 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 16021 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 40 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 50 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 103 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 253 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1974 | 14 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 1305 | 0.010 |
Why?
|
| Arachidonic Acids | 1 | 1974 | 19 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1995 | 369 | 0.010 |
Why?
|
| Tritium | 1 | 1974 | 173 | 0.010 |
Why?
|
| Immune Sera | 1 | 1974 | 95 | 0.010 |
Why?
|
| Gene Library | 1 | 1995 | 220 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1995 | 91 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1974 | 11 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 661 | 0.010 |
Why?
|
| Knee Joint | 1 | 1975 | 160 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1974 | 46 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1974 | 37 | 0.010 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1974 | 65 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1995 | 571 | 0.010 |
Why?
|
| Neutrophils | 2 | 1991 | 372 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 354 | 0.010 |
Why?
|
| Diarrhea | 1 | 1996 | 316 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1996 | 445 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1987 | 396 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 861 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 120 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1995 | 326 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1987 | 442 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 803 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1979 | 4346 | 0.010 |
Why?
|
| Neoplasm Metastasis | 3 | 1982 | 650 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1996 | 334 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1983 | 47 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 10 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 617 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1974 | 351 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 1584 | 0.010 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 1992 | 41 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1999 | 4271 | 0.010 |
Why?
|
| Triethylenephosphoramide | 1 | 1991 | 1 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 1009 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1988 | 2813 | 0.010 |
Why?
|
| Prolactin | 2 | 1982 | 104 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 16 | 0.010 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 1 | 1990 | 1 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1991 | 66 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 1996 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1990 | 57 | 0.010 |
Why?
|
| Spine | 1 | 1991 | 143 | 0.010 |
Why?
|
| Glucose | 1 | 1974 | 872 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1992 | 421 | 0.010 |
Why?
|
| RNA Probes | 1 | 1989 | 30 | 0.010 |
Why?
|
| Body Fluids | 1 | 1990 | 48 | 0.010 |
Why?
|
| Agammaglobulinemia | 2 | 1981 | 39 | 0.010 |
Why?
|
| Arginine | 2 | 1982 | 303 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1992 | 240 | 0.010 |
Why?
|
| Incidence | 1 | 1997 | 3047 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1989 | 2525 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1989 | 391 | 0.010 |
Why?
|
| Succinimides | 1 | 1989 | 7 | 0.010 |
Why?
|
| Ricin | 1 | 1989 | 12 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1989 | 54 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1989 | 179 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1997 | 2838 | 0.000 |
Why?
|
| Verapamil | 1 | 1988 | 52 | 0.000 |
Why?
|
| CD3 Complex | 1 | 1988 | 82 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1992 | 809 | 0.000 |
Why?
|
| Pregnancy | 1 | 1980 | 7148 | 0.000 |
Why?
|
| Triglycerides | 2 | 1982 | 562 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1988 | 368 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 183 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1988 | 223 | 0.000 |
Why?
|
| Adaptation, Psychological | 1 | 1990 | 459 | 0.000 |
Why?
|
| KB Cells | 1 | 1987 | 5 | 0.000 |
Why?
|
| Vinblastine | 1 | 1987 | 46 | 0.000 |
Why?
|
| Insulin | 2 | 1982 | 1200 | 0.000 |
Why?
|
| Bilirubin | 1 | 1987 | 120 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1987 | 258 | 0.000 |
Why?
|
| Transcriptional Activation | 1 | 1987 | 481 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1987 | 609 | 0.000 |
Why?
|
| Melanoma | 1 | 1992 | 824 | 0.000 |
Why?
|
| Brain Damage, Chronic | 1 | 1984 | 30 | 0.000 |
Why?
|
| Fasting | 1 | 1986 | 297 | 0.000 |
Why?
|
| Interphase | 1 | 1984 | 45 | 0.000 |
Why?
|
| Atrophy | 1 | 1984 | 226 | 0.000 |
Why?
|
| Reaction Time | 1 | 1984 | 172 | 0.000 |
Why?
|
| Eating | 1 | 1986 | 372 | 0.000 |
Why?
|
| Genetic Code | 1 | 1983 | 40 | 0.000 |
Why?
|
| Streptodornase and Streptokinase | 1 | 1982 | 1 | 0.000 |
Why?
|
| Bacteria | 1 | 1987 | 482 | 0.000 |
Why?
|
| Methods | 1 | 1982 | 147 | 0.000 |
Why?
|
| Gonadotropins | 1 | 1982 | 35 | 0.000 |
Why?
|
| Candida | 1 | 1982 | 75 | 0.000 |
Why?
|
| Stem Cells | 1 | 1987 | 700 | 0.000 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1981 | 6 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1988 | 1480 | 0.000 |
Why?
|
| Levodopa | 1 | 1982 | 90 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1981 | 120 | 0.000 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1981 | 26 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1987 | 1695 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1984 | 448 | 0.000 |
Why?
|
| Sperm Count | 1 | 1981 | 75 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1981 | 12 | 0.000 |
Why?
|
| Goats | 1 | 1980 | 55 | 0.000 |
Why?
|
| Prospective Studies | 2 | 1982 | 6033 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1980 | 64 | 0.000 |
Why?
|
| Puberty | 1 | 1981 | 94 | 0.000 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1981 | 88 | 0.000 |
Why?
|
| Acetazolamide | 1 | 1980 | 30 | 0.000 |
Why?
|
| Hemocyanins | 1 | 1979 | 27 | 0.000 |
Why?
|
| Listeriosis | 1 | 1979 | 19 | 0.000 |
Why?
|
| Uric Acid | 1 | 1980 | 94 | 0.000 |
Why?
|
| Fever of Unknown Origin | 1 | 1979 | 45 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1979 | 145 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1982 | 1309 | 0.000 |
Why?
|
| Carmustine | 1 | 1978 | 26 | 0.000 |
Why?
|
| Histiocytes | 1 | 1978 | 23 | 0.000 |
Why?
|
| Endotoxins | 1 | 1978 | 47 | 0.000 |
Why?
|
| Cerebral Ventriculography | 1 | 1977 | 2 | 0.000 |
Why?
|
| Gold Colloid, Radioactive | 1 | 1977 | 1 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1977 | 67 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1977 | 105 | 0.000 |
Why?
|
| Biopharmaceutics | 1 | 1977 | 1 | 0.000 |
Why?
|
| Spleen | 1 | 1978 | 272 | 0.000 |
Why?
|
| Syndrome | 1 | 1980 | 1115 | 0.000 |
Why?
|
| Myocarditis | 1 | 1978 | 119 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1981 | 533 | 0.000 |
Why?
|
| Cell Division | 1 | 1978 | 780 | 0.000 |
Why?
|
| Hyperlipidemias | 1 | 1978 | 173 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1975 | 39 | 0.000 |
Why?
|
| Lectins | 1 | 1975 | 49 | 0.000 |
Why?
|
| Antibodies, Neoplasm | 1 | 1975 | 58 | 0.000 |
Why?
|
| Optic Nerve | 1 | 1977 | 117 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1987 | 2394 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1977 | 360 | 0.000 |
Why?
|
| Hepatitis B virus | 1 | 1976 | 136 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1974 | 18 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1974 | 69 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1976 | 435 | 0.000 |
Why?
|
| Immunization | 1 | 1975 | 308 | 0.000 |
Why?
|
| Blood Donors | 1 | 1974 | 62 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1974 | 148 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1976 | 1168 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1976 | 1135 | 0.000 |
Why?
|